Postural Orthostatic Tachycardia Syndrome (POTS)
Postural Orthostatic Tachycardia Syndrome (POTS) is a clinical syndrome characterized by a sustained heart rate increase of ≥30 bpm (or ≥40 bpm in those 12-19 years old) within 10 minutes of standing, absence of orthostatic hypotension, and frequent symptoms of orthostatic intolerance that persist for at least 3 months. 1
Diagnostic Criteria
POTS is diagnosed based on the following specific criteria:
Heart rate increase:
Blood pressure response:
- Absence of orthostatic hypotension (no sustained systolic blood pressure drop of ≥20 mm Hg) 2
Symptom profile:
Duration:
- Symptoms present for at least 3 months 2
Exclusion criteria:
- Absence of other conditions explaining sinus tachycardia such as:
- Anorexia nervosa
- Primary anxiety disorders
- Hyperventilation
- Anemia
- Fever, pain, infection
- Dehydration
- Hyperthyroidism
- Pheochromocytoma
- Use of cardioactive drugs
- Severe deconditioning from prolonged bed rest 2
- Absence of other conditions explaining sinus tachycardia such as:
Pathophysiology
POTS is heterogeneous with three primary phenotypes identified:
Hyperadrenergic POTS:
- Characterized by excessive norepinephrine production or impaired reuptake
- Results in sympathetic overactivity 3
Neuropathic POTS:
- Impaired vasoconstriction during orthostatic stress
- Often involves peripheral sympathetic denervation 3
Hypovolemic POTS:
- Associated with reduced blood volume
- Often triggered by dehydration and physical deconditioning 3
Clinical Presentation
Patients with POTS typically present with:
- Dizziness and lightheadedness upon standing
- Rapid heartbeat and palpitations
- Weakness and fatigue
- Physical deconditioning and reduced exercise capacity
- Headache and "brain fog" (cognitive difficulties)
- Dyspnea
- Gastrointestinal symptoms
- Musculoskeletal pain 4
Common Triggers and Associations
POTS onset is often precipitated by:
Post-COVID POTS
Recent evidence indicates that 2%-14% of COVID-19 survivors develop POTS, with 9%-61% experiencing POTS-like symptoms within 6-8 months of SARS-CoV-2 infection. This specific form of POTS is now recognized as part of post-acute COVID-19 syndrome (PASC POTS) 2, 5.
Management Approach
Management of POTS focuses on:
Non-pharmacological interventions (first-line for all patients):
Pharmacological therapy (tailored to phenotype):
Prognosis
Although long-term prognosis is not well-established, approximately 50% of patients spontaneously recover within 1-3 years. However, many patients experience persistent symptoms that can significantly impact quality of life 4.
Key Clinical Considerations
- POTS predominantly affects females (≈80%) between 15-45 years old
- Prevalence ranges from 0.2% to 1.0% in developed countries
- Diagnostic testing should include head-up tilt test with non-invasive beat-to-beat hemodynamic monitoring
- POTS can be mistaken for anxiety disorders or deconditioning
- A multidisciplinary approach involving cardiology, neurology, and rehabilitation medicine often yields the best outcomes 4, 6